Given the pivotal role of LIF, bFGF, VEGF-A and IL-8 in tumourigenesis and their correlated secretion in OAC, the potential of targeting these growth factors and cytokines to improve patient response to neoadjuvant treatment and to inhibit tumour progression in OAC must be investigated in future studies. This evidence concerns the gene CXCL8 and neoplasm.